ES2171591T3 - Nueva forma de dosificacion de hidroxocobalamina y su uso en el envenenamiento por cianuro. - Google Patents

Nueva forma de dosificacion de hidroxocobalamina y su uso en el envenenamiento por cianuro.

Info

Publication number
ES2171591T3
ES2171591T3 ES96117314T ES96117314T ES2171591T3 ES 2171591 T3 ES2171591 T3 ES 2171591T3 ES 96117314 T ES96117314 T ES 96117314T ES 96117314 T ES96117314 T ES 96117314T ES 2171591 T3 ES2171591 T3 ES 2171591T3
Authority
ES
Spain
Prior art keywords
hydroxocobalamine
dosage
poisoning
new method
cyanide poisoning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96117314T
Other languages
English (en)
Inventor
Gerard Pouchol
Yves Bonhomme
Marie-Laure Poulain
Michel Durand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2171591T3 publication Critical patent/ES2171591T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION HACE REFERENCIA AL CAMPO FARMACEUTICO, Y MAS ESPECIALMENTE A LA QUIMICA TERAPEUTICA. SE HACE REFERENCIA A UNA NUEVA FORMA DE DOSIFICACION DE HIDROXOCOBALAMINA QUE TIENE UTILIDAD EN EL TRATAMIENTO DEL ENVENENAMIENTO POR CIANIDA. LAS NUEVAS COMPOSICIONES FARMACEUTICAS DE ACUERDO CON LA INVENCION CONTIENEN HIDROXOCOBALAMINA EN FORMA SECADA EN PUNTO DE CONGELACION. LA HIDROXOCABALAMINA ES SECADA EN PUNTO DE CONGELACION EN UN MEDIO ACIDICO PARA SER PRACTICAMENTE DE FORMA INSTANTANEA REDISUELTA EN UNA SOLUCION SALINA NEUTRAL. LA PRESENTE INVENCION TAMBIEN HACE REFERENCIA A UN PROCESO PARA PRODUCIR COMPOSICIONES FARMACEUTICAS BASADAS EN HIDROXOCOBALAMINA ASI COMO EL PRIMER EQUIPO DE AYUDA QUE CONTIENE ESTAS COMPOSICIONES. SE UTILIZA PARA EL TRATAMIENTO DE LOS ENVENENAMIENTO POR CIANIDA.
ES96117314T 1995-11-15 1996-10-29 Nueva forma de dosificacion de hidroxocobalamina y su uso en el envenenamiento por cianuro. Expired - Lifetime ES2171591T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9513512A FR2740973B1 (fr) 1995-11-15 1995-11-15 Nouvelle forme d'administration de l'hydroxocobalamine et son utilisation dans les intoxications par les cyanures

Publications (1)

Publication Number Publication Date
ES2171591T3 true ES2171591T3 (es) 2002-09-16

Family

ID=9484577

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96117314T Expired - Lifetime ES2171591T3 (es) 1995-11-15 1996-10-29 Nueva forma de dosificacion de hidroxocobalamina y su uso en el envenenamiento por cianuro.

Country Status (10)

Country Link
US (1) US5834448A (es)
EP (1) EP0775485B1 (es)
JP (1) JP3699223B2 (es)
AU (1) AU720219B2 (es)
DE (1) DE69619767T2 (es)
DK (1) DK0775485T3 (es)
ES (1) ES2171591T3 (es)
FR (1) FR2740973B1 (es)
IS (1) IS1880B (es)
NO (1) NO315495B1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100341950B1 (ko) * 1993-07-19 2002-11-29 도레이 가부시끼가이샤 뇌세포보호제
AR022986A1 (es) * 1996-08-12 2002-09-04 Gist Brocades Bv Produccion y uso de composiciones que comprenden concentraciones altas de actividad de vitamina b12
CA2521928A1 (en) * 2003-05-07 2004-11-18 Eisai Co., Ltd. Freeze-dried preparation containing methylcobalamin and process for producing the same
US9585908B1 (en) * 2010-11-08 2017-03-07 Chromaceutical Advanced Technologies, Inc. Collyrium composition and method of using same
US9757354B2 (en) * 2015-06-08 2017-09-12 Regents Of The University Of Minnesota Therapeutic formulations and methods
US11925623B2 (en) 2020-07-21 2024-03-12 Regents Of The University Of Minnesota Methods for the treatment of conditions related to hydrogen sulfide
TWI818601B (zh) 2021-10-29 2023-10-11 原創生醫股份有限公司 用於上呼吸道給藥之組成物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788780A (fr) * 1971-09-21 1973-01-02 Rolland Sa A Procede pour le diagnostic de l'hypercyanurie
FR2534809B1 (fr) * 1982-10-26 1985-06-28 Roussel Uclaf Association medicamenteuse, renfermant a titre de principes actifs, un analgesique central et la vitamine b 12 ou un derive de celle-ci

Also Published As

Publication number Publication date
DK0775485T3 (da) 2002-05-06
DE69619767D1 (de) 2002-04-18
FR2740973A1 (fr) 1997-05-16
JP3699223B2 (ja) 2005-09-28
AU7172096A (en) 1997-05-22
NO315495B1 (no) 2003-09-15
US5834448A (en) 1998-11-10
EP0775485A1 (en) 1997-05-28
AU720219B2 (en) 2000-05-25
DE69619767T2 (de) 2002-10-10
NO964825D0 (no) 1996-11-14
IS4387A (is) 1997-05-16
IS1880B (is) 2003-08-15
EP0775485B1 (en) 2002-03-13
FR2740973B1 (fr) 1998-02-06
JPH09136837A (ja) 1997-05-27
NO964825L (no) 1997-05-16

Similar Documents

Publication Publication Date Title
UY23992A1 (es) Procedimiento para la preparación de compuestos de 1-fenil-3-dimetilamino-propano
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
UY26496A1 (es) Composiciones farmacéuticas que proporcionan concentraciones potenciadas de fármaco
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
ES2183937T3 (es) Inhibidores de la adhesion celular.
ES2188656T3 (es) Composicion antiviral para la cicatrizacion de una herida que contiene un piruvato, un antioxidante, una mezcla de acidos grasos saturados y un compuesto antiviral.
ES2152222T3 (es) Sulfonamidas, su preparacion y su uso como medicamento e intermedio.
UY27740A1 (es) Nuevos compuestos
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
CY1109229T1 (el) Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
GT199900203A (es) Composiciones de celecoxib.
ES2090131T3 (es) Solucion antineoplasica y procedimiento para el tratamiento de neoplasmas.
MX9709874A (es) N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
ES2054716T3 (es) Bis-naftalimidas, su obtencion y empleo.
ES2194935T3 (es) Preparados estables de transglutaminasa y procedimiento para su preparacion.
MX9308013A (es) 4-fenil-piridonas y 4-fenil-2-fenil-2-alcoxipiridinas sustituidas, procedimiento para su preparacion y medicamentos que los contienen.
PA8577201A1 (es) 3-fenil-propionamido, 3-fenil-acrilamido y derivados 3-fenil-propinamido como inhibidores de mao-b
ES2170759T3 (es) Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.
ES2171591T3 (es) Nueva forma de dosificacion de hidroxocobalamina y su uso en el envenenamiento por cianuro.
PE20050108A1 (es) Manguito y parche analgesico microencapsulado de uso topico para el tratamiento del dolor
MX9207557A (es) Derivados de acidos benzofuranil- y tiofenilmetiltio-alcanocarboxilicos, procedimiento para su preparacion y medicamentos que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 775485

Country of ref document: ES